CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

NCT05454241 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: Anti-CD7 CAR-T

Sponsor

Institute of Hematology & Blood Diseases Hospital, China